Medical Device | May 20, 2022
Olympus announces exclusive U.S. co-marketing agreement with Bracco Diagnostics
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The MoU was signed on World Organ Donation Day which falls on August 13
Subscribe To Our Newsletter & Stay Updated
